We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
FDA, BPDCN에 대해 pivekimab sunirin (Decnupaz) 승인, 완전 관해율 69.7%. 효능, 위험, 가격 및 AML에서의 전망 분석. 자세히 보기.
